Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/21349172http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/21349172http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/21349172http://www.w3.org/2000/01/rdf-schema#comment"

Background

Fibroblast growth factor receptor 4 (FGFR4) displays multiple biological activities, including mitogenic and angiogenic activity, and plays important roles in the etiology and progression of prostate cancer. Gly388Arg polymorphism in FGFR4 gene has been reported to be involved in prostate cancer incidence and aggressiveness in several studies. To derive a more precise estimation of the relationship, a meta-analysis was performed.

Methods

Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association.

Results

The Arg388 allele increased prostate cancer risk compared with Gly388 allele (OR = 1.17, 95% CI = 1.07-1.29). When stratified by race, there was a significantly increased prostate cancer risk in Asian and Caucasian populations. Moreover, prostate cancer patients with Arg/Arg genotype had a 1.34-fold increased risk of advanced prostate cancer (95% CI: 1.03-1.74) compared with those with Gly/Gly+Gly/Arg genotype.

Conclusion

This meta-analysis showed the evidence that FGFR4 Gly388Arg polymorphism was associated with an increased risk of prostate cancer development and progression, suggesting that FGFR4 Gly388Arg polymorphism could be a marker for prostate cancer development and progression."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.org/dc/terms/identifier"doi:10.1186/1471-2407-11-84"xsd:string
http://purl.uniprot.org/citations/21349172http://purl.org/dc/terms/identifier"doi:10.1186/1471-2407-11-84"xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Chen M."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Chen M."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Xu B."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Xu B."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Zhang Z.D."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Zhang Z.D."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Wang Z.J."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Wang Z.J."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Chen S.Q."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Chen S.Q."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Hua L.X."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Hua L.X."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Tong N."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/author"Tong N."xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/date"2011"xsd:gYear
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/date"2011"xsd:gYear
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/name"BMC Cancer"xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/name"BMC Cancer"xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/pages"84"xsd:string
http://purl.uniprot.org/citations/21349172http://purl.uniprot.org/core/pages"84"xsd:string
▶